Tandem Diabetes Care Reports Q3 2026 Growth Driven by International Expansion and Mobi Platform

Tandem Diabetes Care (TNDM) reported strong third-quarter results for 2026, with worldwide sales reaching $283.7 million, a 14% increase year-over-year. The growth was primarily fueled by robust international demand and the successful rollout of the Tandem Mobi platform, which saw significant conversion from multiple daily injection users. International sales grew 26%, supported by direct market execution in several countries. The company demonstrated improved profitability with gross margins rising to 57% and Adjusted EBITDA reaching $18 million (6% of sales). While transitioning to a new pharmacy reimbursement model created some headwinds, Tandem reaffirmed its full-year sales guidance of $1.065 billion to $1.085 billion. The company maintains a strong liquidity position with $443 million in cash and investments.

6 articles from 2 sources · updated

Coverage